TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Oryzon Genomics SA ( (ES:ORY) ).
Oryzon Genomics SA has announced a capital increase of 25 million euros through an accelerated private placement of ordinary shares. The funds will be used to enhance clinical development in CNS diseases and oncology, prepare for drug manufacturing, and strengthen the balance sheet for potential partnerships and Nasdaq listing.
More about Oryzon Genomics SA
Oryzon Genomics SA is a company operating in the biotechnology industry, focusing on clinical development in central nervous system diseases, oncology, and hematology. The company is also involved in drug manufacturing preparations and aims to strengthen its financial position for potential partnerships and mergers.
YTD Price Performance: 79.67%
Average Trading Volume: 2,671
Technical Sentiment Signal: Sell
Current Market Cap: €190.9M
For detailed information about ORY stock, go to TipRanks’ Stock Analysis page.